1. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. Issue 11 (27th November 2018) Authors: Hodgson, Darren; Dougherty, Brian; Lai, Zhongwu; Fielding, Anitra; Grinsted, Lynda; Spencer, Stuart; O'Connor, Mark; Ho, Tony; Robertson, Jane; Lanchbury, Jerry; Timms, Kirsten; Gutin, Alexander; Orr, Maria; Jones, Helen; Gilks, Blake; Womack, Chris; Gourley, Charlie; Ledermann, Jonathan; Barrett... Journal: British journal of cancer Issue: Volume 119:Issue 11(2018) Page Start: 1401 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Issue 9 (30th October 2018) Authors: Friedlander, Michael; Matulonis, Ursula; Gourley, Charlie; du Bois, Andreas; Vergote, Ignace; Rustin, Gordon; Scott, Clare; Meier, Werner; Shapira-Frommer, Ronnie; Safra, Tamar; Matei, Daniela; Shirinkin, Vadim; Selle, Frédéric; Fielding, Anitra; Lowe, Elizabeth; McMurtry, Emma; Spencer, Stuart; ... Journal: British journal of cancer Issue: Volume 119:Issue 9(2018) Page Start: 1075 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. (19th January 2016) Authors: Leichman, Lawrence; Groshen, Susan; O'Neil, Bert H.; Messersmith, Wells; Berlin, Jordan; Chan, Emily; Leichman, Cynthia G.; Cohen, Steven J.; Cohen, Deirdre; Lenz, Heinz-Josef; Gold, Philip; Boman, Bruce; Fielding, Anitra; Locker, Gershon; Cason, Ronald C.; Hamilton, Stan R.; Hochster, Howard S. Journal: Oncologist Issue: Volume 21:Number 2(2016) Page Start: 172 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Issue 11 (November 2016) Authors: Ledermann, Jonathan A; Harter, Philipp; Gourley, Charlie; Friedlander, Michael; Vergote, Ignace; Rustin, Gordon; Scott, Clare; Meier, Werner; Shapira-Frommer, Ronnie; Safra, Tamar; Matei, Daniela; Fielding, Anitra; Spencer, Stuart; Rowe, Philip; Lowe, Elizabeth; Hodgson, Darren; Sovak, Mika A; Ma... Journal: Lancet oncology Issue: Volume 17:Issue 11(2016:Nov.) Page Start: 1579 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Phase II Study of Olaparib (AZD‐2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. (19th January 2016) Authors: Leichman, Lawrence; Groshen, Susan; O'Neil, Bert H.; Messersmith, Wells; Berlin, Jordan; Chan, Emily; Leichman, Cynthia G.; Cohen, Steven J.; Cohen, Deirdre; Lenz, Heinz‐Josef; Gold, Philip; Boman, Bruce; Fielding, Anitra; Locker, Gershon; Cason, Ronald C.; Hamilton, Stan R.; Hochster, Howard S. Journal: Oncologist Issue: Volume 21:Number 2(2016) Page Start: 172 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Issue 12 (8th April 2016) Authors: Matulonis, Ursula A.; Harter, Philipp; Gourley, Charlie; Friedlander, Michael; Vergote, Ignace; Rustin, Gordon; Scott, Clare; Meier, Werner; Shapira‐Frommer, Ronnie; Safra, Tamar; Matei, Daniela; Fielding, Anitra; Spencer, Stuart; Parry, David; Grinsted, Lynda; Ledermann, Jonathan A. Journal: Cancer Issue: Volume 122:Issue 12(2016) Page Start: 1844 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. (May 2023) Authors: Robson, Mark E.; Im, Seock-Ah; Senkus, Elzbieta; Xu, Binghe; Domchek, Susan M.; Masuda, Norikazu; Delaloge, Suzette; Tung, Nadine; Armstrong, Anne; Dymond, Mike; Fielding, Anitra; Allen, Allison; Conte, Pierfranco Journal: European journal of cancer Issue: Volume 184(2023) Page Start: 39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗